HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Meet The Quitters: Perrigo Profiles NRT Users To Help UK Pharmacists Drive OTC Smoking Cessation Sales

Executive Summary

To coincide with Stoptober, Perrigo is extending its pharmacy-focused UK marketing strategy for leading smoking cessation brand NiQuitin with research-based sales advice for pharmacists centered on five types of "quitter."

You may also be interested in...



Perrigo To Launch UK Private-Label Viagra Connect Competitor

Perrigo is launching in the UK an OTC sildenafil generic to compete with Pfizer's erectile dysfunction drug Viagra Connect. 

Less Success 'Expected' In 'OTC Setting' Trial For GSK's NRT, Expert Tells NDAC

While lower than  results in GSK standard efficacy trial, 'real world' success still is clinically significant, firm's experts tell FDA advisory committee after agency officials asked the panel to consider whether the results translate to clinically meaningful benefit for GSK's proposed mouth spray NRT.

NDAC Recommendation To Approve GSK's Mouth Spray NRT Comes With Caveats

No more than three votes decided the panel's recommendation on each FDA question, and members in the prevailing majorities explained they made their votes with reservations. Potential use by young consumers and confusion by adult users in following the label instructions were primary concerns for all panel members.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM013057

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel